BioAffinity Non Current Liabilities Total from 2010 to 2024

BIAFW Stock  USD 0.57  0.13  18.57%   
BioAffinity Technologies Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioAffinity Technologies Non Current Liabilities Total regression line of quarterly data had mean square error of 919.9 B and geometric mean of  3,156,453. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2010-12-31
Previous Quarter
1.1 M
Current Value
M
Quarterly Volatility
1.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of bioAffinity Technologies Warrant over the last few years. It is BioAffinity Technologies' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

BioAffinity Non Current Liabilities Total Regression Statistics

Arithmetic Mean3,533,259
Geometric Mean3,156,453
Coefficient Of Variation34.46
Mean Deviation917,468
Median4,097,784
Standard Deviation1,217,443
Sample Variance1.5T
Range3.6M
R-Value(0.65)
Mean Square Error919.9B
R-Squared0.42
Significance0.01
Slope(177,193)
Total Sum of Squares20.8T

BioAffinity Non Current Liabilities Total History

2024M
20231.1 M
2022596.8 K
20214.2 M

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total1.1 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.